ORTHOFIX GAINING DIRECT U.S. SALES FORCE, BONE GROWTH STIMULATORS THROUGH AME ACQUISITION; BIOMET'S EBI LAUNCHING ITS OWN EXTERNAL FIXATION DEVICES
This article was originally published in The Gray Sheet
Executive SummaryOrthofix is hoping the addition of American Medical Electronics' direct sales force will stimulate U.S. sales of its external fixation products. The company stands to gain up to 95 direct U.S. reps through its definitive agreement to purchase AME for $79 mil.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.